However, certain anti-IL17A mAbs such as CNTO 6785 have been shown to exacerbate COPD-related bacterial infections in patients, while several others such as COVA322, NI-1401, secukinumab or brodalumab are yet to be tested on COPD patients (73). Here, IL17A is linked to chronic obstructive pulmonary disease.